Fludarabine and cyclophosphamide

Phase 1Cell therapy

BBeijing Immunochina Medical Science & Technology Co., Ltd.

Fludarabine and cyclophosphamide is one of 52 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Plasma Cell NeoplasmActive, not recruiting

High RiskRecruiting

LymphomaPhase 1

Active, not recruiting

Plasma Cell NeoplasmPhase 1

Active, not recruiting

High RiskPhase 1

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Fludarabine and cyclophosphamide

BBeijing Immunochina Medical Science & Technology Co., Ltd.

Phase 1

2 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

High Risk

NCT07416682

Q3 2028

Phase 1Not yet recruiting

Plasma Cell Neoplasm

NCT06986434

Clinical

Trials by Indication[1]

Lymphoma2 trials

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

Enrolling by invitation·UUniversity of Maryland, Baltimore·Phase 1·NCT07168486·15 enrolled

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Unknown status·PPeking University·Phase 1·NCT03208556·20 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Completed·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·NCT03173417·177 enrolled

Plasma Cell Neoplasm1 trial

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Not yet recruiting·—·Phase 1·NCT06986434·20 enrolled

Chidamide1 trial

Chidamide Bridging for CAR-T Therapy

Recruiting·—·Phase 1/2·NCT05370547·120 enrolled

High Risk1 trial

Clinical Study on the Safety and Efficacy of CAR BCMA-CD70 Dual-target CAR-T Therapy for High-risk Plasma Cell Neoplasms

Recruiting·AAffiliated Hospital to Academy of Military Medical Sciences·Phase 1·NCT07416682·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Fludarabine and cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludarabine and cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludarabine and cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Immunochina Medical Science & Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: BBeijing Immunochina Medical Science & Technology Co., Ltd.

Fludarabine and cyclophosphamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Trials by Indication[1]

Lymphoma2 trials

Safety and Efficacy1 trial

Plasma Cell Neoplasm1 trial

Chidamide1 trial

High Risk1 trial

References

Drug Info

Quick Facts

Related News